These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

59 related articles for article (PubMed ID: 17038655)

  • 1. Asymmetric dimethylarginine and cerebrovascular disorders in humans.
    Tsuda K
    Stroke; 2006 Dec; 37(12):2870; author reply 2871. PubMed ID: 17038655
    [No Abstract]   [Full Text] [Related]  

  • 2. Asymmetric dimethylarginine and hypertension in cerebral small vessel disease.
    Tsuda K
    Stroke; 2007 Jul; 38(7):e48; author reply e49. PubMed ID: 17510451
    [No Abstract]   [Full Text] [Related]  

  • 3. Elevated plasma concentrations of the endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine in citrullinemia.
    Lücke T; Tsikas D; Kanzelmeyer N; Vaske B; Das AM
    Metabolism; 2006 Dec; 55(12):1599-603. PubMed ID: 17142130
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Asymmetric dimethylarginine, derangements of the endothelial nitric oxide synthase pathway, and cardiovascular diseases.
    Böger RH; Bode-Böger SM
    Semin Thromb Hemost; 2000; 26(5):539-45. PubMed ID: 11129410
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma concentration of asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, is elevated in hyperthyroid patients.
    Hermenegildo C; Medina P; Peiró M; Segarra G; Vila JM; Ortega J; Lluch S
    J Clin Endocrinol Metab; 2002 Dec; 87(12):5636-40. PubMed ID: 12466365
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [ADMA (asymmetric dimethylarginine)--the inhibitor of nitric oxide (NO) synthesis: a new marker for vascular pathology].
    Sela BA
    Harefuah; 2005 Sep; 144(9):655-9, 675, 674. PubMed ID: 16218539
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Asymmetric dimethylarginine: a new player in the pathogenesis of renal disease?
    Zoccali C; Kielstein JT
    Curr Opin Nephrol Hypertens; 2006 May; 15(3):314-20. PubMed ID: 16609301
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Asymmetric dimethylarginine and endothelial dysfunction].
    Yoshizumi M
    Nihon Rinsho; 2004 Sep; 62 Suppl 9():555-60. PubMed ID: 15506448
    [No Abstract]   [Full Text] [Related]  

  • 9. [Asymmetric dimethylarginine: predictor of cardiovascular diseases?].
    Németh B; Kustán P; Németh Á; Lenkey Z; Cziráki A; Kiss I; Sulyok E; Ajtay Z
    Orv Hetil; 2016 Mar; 157(13):483-7. PubMed ID: 26996894
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of l-arginine transport in platelets by asymmetric dimethylarginine and N-monomethyl-l-arginine: effects of arterial hypertension.
    Brunini T; Moss M; Siqueira M; Meirelles L; Rozentul A; Mann G; Ellory J; Soares de Moura R; Mendes-Ribeiro A
    Clin Exp Pharmacol Physiol; 2004 Oct; 31(10):738-40. PubMed ID: 15554917
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Asymmetric dimethylarginine (ADMA) in vascular, renal and hepatic disease and the regulatory role of L-arginine on its metabolism.
    Wilcken DE; Sim AS; Wang J; Wang XL
    Mol Genet Metab; 2007 Aug; 91(4):309-17; discussion 308. PubMed ID: 17560156
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulation of macrophage nitric oxide synthesis by endothelial cells: a role for NG,NG-dimethylarginine.
    Fickling SA; Holden DP; Cartwright JE; Nussey SS; Vallance P; Whitley GS
    Acta Physiol Scand; 1999 Oct; 167(2):145-50. PubMed ID: 10571550
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiovascular biology of the asymmetric dimethylarginine:dimethylarginine dimethylaminohydrolase pathway.
    Vallance P; Leiper J
    Arterioscler Thromb Vasc Biol; 2004 Jun; 24(6):1023-30. PubMed ID: 15105281
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Asymmetric dimethylarginine: a molecule responsible for the coexistence of insulin resistance and atherosclerosis via dual nitric oxide synthase inhibition.
    Zsuga J; Gesztelyi R; Török J; Kéki S; Bereczki D
    Med Hypotheses; 2005; 65(6):1091-8. PubMed ID: 16125868
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Asymmetrical dimethylarginine: the Uber marker?
    Cooke JP
    Circulation; 2004 Apr; 109(15):1813-8. PubMed ID: 15096461
    [No Abstract]   [Full Text] [Related]  

  • 16. ADMA and the brain: an unfolding story.
    Kielstein JT; Kielstein A
    Am J Hypertens; 2009 Mar; 22(3):240. PubMed ID: 19229207
    [No Abstract]   [Full Text] [Related]  

  • 17. Suppression of endothelial progenitor cells in human coronary artery disease by the endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine.
    Thum T; Tsikas D; Stein S; Schultheiss M; Eigenthaler M; Anker SD; Poole-Wilson PA; Ertl G; Bauersachs J
    J Am Coll Cardiol; 2005 Nov; 46(9):1693-701. PubMed ID: 16256870
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of asymmetric dimethylarginine and arginine in the failing heart and its vasculature.
    Visser M; Paulus WJ; Vermeulen MA; Richir MC; Davids M; Wisselink W; de Mol BA; van Leeuwen PA
    Eur J Heart Fail; 2010 Dec; 12(12):1274-81. PubMed ID: 20923854
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Asymmetric dimethylarginine reduced erythrocyte deformability in streptozotocin-induced diabetic rats.
    Yang ZC; Xia K; Wang L; Jia SJ; Li D; Zhang Z; Deng S; Zhang XH; Deng HW; Li YJ
    Microvasc Res; 2007 Mar; 73(2):131-6. PubMed ID: 17098259
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Asymmetric dimethylarginine: metabolism, arginine paradox, pathophysiology].
    Gilinskiĭ MA
    Usp Fiziol Nauk; 2007; 38(3):21-39. PubMed ID: 17977229
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.